Pharma news
Americas
The US Food and Drug Administration has introduced a rule enabling it to destroy certain drugs that have been refused entry into the US. 17 September 2015
Asia
The Indian Pharmaceutical Alliance has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi. 16 September 2015
Pharma
The English High Court has ruled that Pfizer’s second medical use patent covering its drug Lyrica (pregabalin) is invalid and that the pharmaceutical company is liable for making “groundless threats” of infringement. 11 September 2015
Pharma
Aldgate Tower will make an ideal home for the UK division of the UPC, with many advantages for its likely users, says Claire Phipps-Jones of Bristows. 10 September 2015
Asia
Pfizer has had a patent application for tofacitinib, which is marketed as Xeljanz and Jakvinus, rejected by the Indian Patent Office for the second time. 8 September 2015
Americas
Biopharmaceutical company Omeros has hit its competitor Par Pharmaceutical with two lawsuits at US district courts over the drug company’s attempt to market a generic version of its Omidria product. 7 September 2015
Americas
Hedge fund manager Kyle Bass’s Coalition for Affordable Drugs has suffered another setback in its bid to knock out allegedly spurious patents after the US Patent and Trademark Office declined to institute an inter partes review of a patent owned by Biogen. 3 September 2015
Americas
Congress has apparently taken note of the strategy of hedge fund manager Kyle Bass to take advantage of the IPR process, with two pending patent reform bills which include provisions that could curtail his activities, says John Abramic of Steptoe & Johnson. 3 September 2015
Americas
Hedge fund manager Kyle Bass’s group the Coalition for Affordable Drugs has targeted two patents owned by the University of Pennsylvania in the latest petition for an inter partes review. 1 September 2015
Pharma
The competence in various areas of the new Unified Patent Court is a matter of conjecture, as Paul England and Christof Höhne of law firm Taylor Wessing report. 27 August 2015